Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × Androgen Antagonists × Clear all

Phase

Phase NA 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 22 Neoplasm Metastasis 3 Prostate Cancer Metastatic 2 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Genital Diseases, Male 1 Abiraterone Acetate 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Capecitabine 12 Gemcitabine 11 Cyclophosphamide 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 6 Prednisone 6 Ondansetron 6 Morphine 6 Irinotecan 6 Drug Therapy 6 Doxorubicin 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5 Sodium Chloride 5 Panitumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01957436 2024-11-12

PEACE1

UNICANCER

Phase 3 Active not recruiting

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡